Market Research Logo

North America Atopic Dermatitis Drugs Market Forecast 2018-2026

North America Atopic Dermatitis Drugs Market Forecast 2018-2026

KEY FINDINGS

North America possesses the largest market for Atopic Dermatitis Drugs across the globe. The region holds half of the volume of the overall market. During the forecasting years, the Atopic Dermatitis Drugs market in North America is proliferating at a CAGR of 4.06%. The advancement of the market is attributable to the rising incidence of the AD and increasing skin and food allergies.

MARKET INSIGHTS

The North America Atopic Dermatitis Drugs market is segmented into drug class, route of administration. The major countries present in the North America region are the United States and Canada. The United States is leading the North America Atopic Dermatitis Drugs market by holding the largest share in the region. In the US, 31.6 million individuals have eczema, of which 17.8 million had moderate to severe eczema or atopic dermatitis which is augmenting the market demand significantly.

COMPETITIVE INSIGHTS

The key companies in the market are Encore Dermatology, Astellas Pharma Inc., Galderma SA, Valent Pharmaceutical Inc., Regeneron Pharmaceuticals, Leo Pharma, Aqua Pharmaceuticals (An Almirall Company), Novartis Ag, Meda Pharmaceuticals (Mylan), Allergan Plc., Sanofi Sa, Pfizer, Stiefel Laboratories Inc., Biofrontera Ag, Bayer Ag, and Bristol-Myers Squibb.


1. Research Scope
1.1. Study Goals
1.2. Scope Of The Market Study
1.3. Who Will Find This Report Useful?
1.4. Study And Forecasting Years
2. Research Methodology
2.1. Sources Of Data
2.1.1. Secondary Data
2.1.2. Primary Data
2.2. Top-down Approach
2.3. Bottom-up Approach
2.4. Data Triangulation
3. Executive Summary
3.1. Market Summary
3.2. Key Findings
3.2.1. Topical Route Of Administration Holds Majority Share Of The Overall Market
3.2.2. Interleukin Inhibitor Is Anticipated To Generate Highest Revenue In The Market
4. Market Dynamics
4.1. Introduction: Atopic Dermatitis
4.2. Market Definition & Scope
4.3. Legal, Policy And Regulatory Issues
4.4. Market Drivers
4.4.1. Growing Prevalence Of Food Allergies Exacerbating Atopic Dermatitis
4.4.2. Growing Focus On Systematic Therapies
4.4.3. Increasing Use Of Pharmacological Products In Developing Countries
4.5. Market Restraints
4.5.1. Stringent Regulations For Product Approval
4.5.2. Generic Competition
4.6. Market Opportunities
4.6.1. Increasing M&A Leading To Market Consolidation
4.6.2. Launch Of First Biologic For Atopic Dermatitis
4.6.3. Growing Focus On Novel Drugs
4.7. Market Challenges
4.7.1. Black Box Warning For Elidel And Protopic
4.7.2. Highly Genercized Market
4.7.3. Poor Patient Adherence Due To Inadequate Information On Drug Usage
5. Market By Route Of Administration (Roa)
5.1. Topical
5.2. Oral
5.3. Injectable
6. Market By Drug Class
6.1. Topical Antibiotics
6.2. Topical Antihistamines
6.3. Topical Corticosteroids
6.4. Topical Moisturizers/Emollients
6.5. Topical Calcineurin Inhibitors
6.6. Immunomodulators
6.7. Off-label Therapies
6.8. Systemic Agents
6.9. Pde-4 Inhibitor
6.10. Interleukin Inhibitor
7. Key Analytics
7.1. Porters Five Force Model
7.1.1. Threat Of New Entrants
7.1.2. Threat Of Substitute
7.1.3. Bargaining Power Of Suppliers
7.1.4. Bargaining Power Of Buyers
7.1.5. Threat Of Competitive Rivalry
7.2. Opportunity Matrix
7.3. Vendor Landscape
7.4. Pipeline Analysis
8. Geographical Analysis
8.1. United States
8.2. Canada
9. Company Profiles
9.1. Allergan Plc.
9.2. Aqua Pharmaceuticals (An Almirall Company)
9.3. Astellas Pharma Inc.
9.4. Bayer Ag
9.5. Biofrontera Ag
9.6. Bristol-myers Squibb
9.7. Stiefel Laboratories Inc
9.8. Encore Dermatology
9.9. Galderma Sa
9.10. Leo Pharma
9.11. Meda Pharmaceuticals (Mylan)
9.12. Novartis Ag
9.13. Pfizer
9.14. Regeneron Pharmaceuticals
9.15. Sanofi Sa
9.16. Valent Pharmaceutical Inc.
List Of Tables
Table 1: North America Atopic Dermatitis Drugs Market, By Geography, 2018-2026 (In $ Million)
Table 2: Regulatory Framework In Atopic Dermatitis Market
Table 3: Recent Mergers And Acquisitions In Atopic Dermatitis Drugs Market
Table 4: North America Atopic Dermatitis Drugs Market, By Roa, 2018-2026, (In $ Million)
Table 5: North America Atopic Dermatitis Drugs Market, By Drug Class, 2018-2026 (In $ Million)
Table 6: Opportunity Matrix For Atopic Dermatitis Drugs Market
Table 7: Vendor Landscape Of Atopic Dermatitis Drugs Market
Table 8: Pipeline Portfolio Of Atopic Dermatitis Drugs Market
Table 9: North America Atopic Dermatitis Drugs Market, By Country, 2018-2026 (In $ Million)
List Of Figures
Figure 1: North America Atopic Dermatitis Drugs Market 2018-2026 (In $ Million)
Figure 2: North America Atopic Dermatitis Drugs Market, By Topical Route Of Administration, 2018-2026 (In $ Million)
Figure 3: North America Atopic Dermatitis Drugs Market, By Interleukin Inhibitor, 2018-2026 (In $ Million)
Figure 4: North America Atopic Dermatitis Drugs Market, By Roa, 2017 & 2026 (In %)
Figure 5: North America Atopic Dermatitis Drugs Market, By Topical, 2018-2026 (In $ Million)
Figure 6: North America Atopic Dermatitis Drugs Market, By Oral, 2018-2026 (In $ Million)
Figure 7: North America Atopic Dermatitis Drugs Market, By Injectable, 2018-2026 (In $ Million)
Figure 8: North America Atopic Dermatitis Drugs Market, By Drug Class, 2017 & 2026 (In %)
Figure 9: North America Atopic Dermatitis Drugs Market, By Topical Antibiotics, 2018-2026 (In $ Million)
Figure 10: North America Atopic Dermatitis Drugs Market, By Topical Antihistamines, 2018-2026 (In $ Million)
Figure 11: North America Atopic Dermatitis Drugs Market, By Topical Corticosteroids, 2018-2026 (In $ Million)
Figure 12: North America Atopic Dermatitis Drugs Market, By Topical Moisturizers/Emollients, 2018-2026 (In $ Million)
Figure 13: North America Atopic Dermatitis Drugs Market, By Topical Calcineurin Inhibitors, 2018-2026 (In $ Million)
Figure 14: North America Atopic Dermatitis Drugs Market, By Immunomodulators, 2018-2026 (In $ Million)
Figure 15: North America Atopic Dermatitis Drugs Market, By Off-label Therapies, 2018-2026 (In $ Million)
Figure 16: North America Atopic Dermatitis Drugs Market, By Systemic Agents, 2018-2026 (In $ Million)
Figure 17: North America Atopic Dermatitis Drugs Market, By Pde-4 Inhibitor, 2018-2026 (In $ Million)
Figure 18: North America Atopic Dermatitis Drugs Market, By Interleukin Inhibitor, 2018-2026 (In $ Million)
Figure 19: Porter’s Five Force Model Of Atopic Dermatitis Drugs Market
Figure 20: North America Atopic Dermatitis Drugs Market, Regional Outlook, 2017 & 2026 (In %)
Figure 21: United States Atopic Dermatitis Drugs Market, 2018-2026 (In $ Million)
Figure 22: Canada Atopic Dermatitis Drugs Market, 2018-2026 (In $ Million)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report